Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Digestive SystemDRG 386-inflammatory-bowel-disease-with-cc
    Ask Trek AI about this page

    Inflammatory Bowel Disease with CC: Inpatient Reimbursement Overview

    DRG 386 captures inpatient stays for inflammatory bowel disease with a Complication or Comorbidity, such as infections, severe fluid and electrolyte disturbances, or other medical complications that raise resource needs. Classification into this Diagnosis-Related Group affects Medicare inpatient reimbursement by reflecting higher expected resource use compared with uncomplicated inflammatory bowel disease.

    Customize your policy alerts

    Sign up for drg 386 policy alerts

    Get alerted when payer policies referencing 386 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 386 Overview

    DRG 386 covers hospital admissions for inflammatory bowel disease with a Complication or Comorbidity, including moderate exacerbations or complications of Crohn disease and ulcerative colitis that require inpatient management. This Diagnosis-Related Group groups cases where an associated diagnosis increases resource use compared with uncomplicated disease. It matters for Medicare payment because the presence of a Complication or Comorbidity alters case classification and influences reimbursement relative to uncomplicated inflammatory bowel disease. Accurate documentation and coding of the inflammatory bowel disease diagnosis and any Complication or Comorbidity determine assignment to this Diagnosis-Related Group.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute hospital-based interventional studies evaluating rapid control of severe flares: randomized or prospective cohort trials that test short-duration interventions (e.g., accelerated anti-inflammatory protocols, optimized IV corticosteroid strategies, or adjunctive rescue therapies) in adults hospitalized with moderate-to-severe inflammatory bowel disease and a complicating comorbidity. These studies enroll patients at the time of admission for an IBD exacerbation with a CC (such as infection, electrolyte disturbance, or anemia) and measure time to clinical remission, need for surgery, length of stay, and in-hospital complication rates. Results directly inform inpatient clinical pathways and resource utilization decisions that affect reimbursement and DRG-level costs.
    • Comparative effectiveness research of maintenance and step-down strategies initiated during hospitalization: pragmatic trials or large observational registry analyses comparing different strategies for transitioning hospitalized patients with IBD and CCs onto maintenance therapy (for example, timing and choice of immunomodulators, biologic initiation vs. delayed outpatient start, or combination versus monotherapy). These studies focus on patients stabilized in the inpatient setting but at high risk for readmission or progression because of the presence of comorbid conditions, and they evaluate outcomes such as 30- and 90-day readmission, medication-related adverse events, outpatient utilization, and cost-effectiveness. Findings help providers optimize discharge plans and help payers predict post-discharge costs and appropriate authorization policies.
    • Post-discharge outcomes and care coordination trials targeting readmission reduction: implementation studies and randomized care-management trials that test multidisciplinary discharge bundles, early outpatient follow-up, telemonitoring, nutritional support, or case management for patients hospitalized with IBD plus complicating CCs (e.g., malnutrition, infections, or cardiopulmonary comorbidities). These trials enroll the high-risk DRG population after discharge and measure readmission rates, emergency department visits, quality-of-life metrics, and total episode-of-care costs over 30–180 days. Evidence from this research is relevant to providers designing transitions-of-care programs and to payers interested in reducing avoidable readmissions and overall episode spending for this DRG.

    Related Codes

    326-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-MCC

    Stomach, Esophageal and Duodenal Procedures with MCC: Inpatient Reimbursement Overview

    327-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-CC

    Stomach, Esophageal and Duodenal Procedures with CC: Inpatient Reimbursement Overview

    328-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITHOUT-CC-MCC

    Stomach, Esophageal and Duodenal Procedures without CC/MCC: Inpatient Reimbursement Overview

    329-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

    Major Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

    330-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-CC

    Major Small and Large Bowel Procedures with CC: Inpatient Reimbursement Overview

    331-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITHOUT-CC-MCC

    Major Small and Large Bowel Procedures without CC/MCC: Inpatient Reimbursement Overview

    332-RECTAL-RESECTION-WITH-MCC

    Rectal Resection with MCC: Inpatient Reimbursement Overview

    333-RECTAL-RESECTION-WITH-CC

    Rectal Resection with CC: Inpatient Reimbursement Overview

    334-RECTAL-RESECTION-WITHOUT-CC-MCC

    Rectal Resection without CC/MCC: Inpatient Reimbursement Overview

    335-PERITONEAL-ADHESIOLYSIS-WITH-MCC

    Peritoneal Adhesiolysis with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 57

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.